Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Month: December 2022
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company”…
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company”…
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product Development MORRISVILLE, N.C.,…
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product Development MORRISVILLE, N.C.,…
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all…
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all…
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a…
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a…
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline WATERTOWN,…
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline WATERTOWN,…